Blog

New research from a team of genome scientists and DNA damage response experts breaks new ground in understanding the function of a protein currently limited in clinical trials for cancer treatments. Credit: UNC Charlotte New research from a team of genome scientists and DNA damage

FOR IMMEDIATE RELEASE Credit: Elizabeth Cook FOR IMMEDIATE RELEASE A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments. Credit: Matt Miller/WashU Medicine By recruiting the immune system to combat tumor

BUFFALO, NY- August 6, 2024 – On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), entitled, “Targeted cancer therapy: the initial high concentration

**EMBARGOED FOR RELEASE UNTIL AUG. 6 AT 11 A.M. ET** Credit: Christopher Jackson, M.D. **EMBARGOED FOR RELEASE UNTIL AUG. 6 AT 11 A.M. ET** A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight

(MEMPHIS, Tenn. – August 5, 2024) Acute lymphoblastic leukemia (ALL) affects both children and adults, but children have better chances to be cured, with long-term survival rates over 85% compared to 50-75% in adults. Scientists at St. Jude Children’s Research Hospital conducted a comprehensive study

OAK BROOK, Ill. – A deep learning model performs at the level of an abdominal radiologist in the detection of clinically significant prostate cancer on MRI, according to a study published today in Radiology, a journal of the Radiological Society of North America (RSNA). The

Some who experience menopause early may be at increased risk for developing breast cancer, according to research led by scientists at Huntsman Cancer Institute at the University of Utah (the U) and the Spencer Fox Eccles School of Medicine at the U. Credit: Huntsman Cancer Institute

(MEMPHIS, Tenn. – August 5, 2024) Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its potential against pediatric solid tumors. Scientists at St. Jude Children’s

BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget’s Volume 15 on July 12, 2024, entitled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction